Since only 10 percent of ALS cases are driven by known genetic mutations1, such as SOD1 or C9orf72, therapeutic interventions directly targeting and correcting for these mutations may prove beneficial, but may not be effective in the majority of sporadic cases. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.